Evidence map›Paper›PMID 40410917›Full record

ArticleActa neuropathologica communications2025

Experimental evidence that readily diffusible forms of Aβ from Alzheimer's disease brain have seeding activity.

Simin Song, Qianmin Liu, Ruixiang Chen, Ping Chen, Min Tao, Siyao Li, Liping Guo, Xixi Zhu, Yan Liu, Lu Liu and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta neuropathologica communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Simin Song *Shenzhen Key Laboratory of Neuroimmunomodulation for Neurological Diseases, Shenzhen- Hong Kong Institute of Brain Science, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518055, China.
Qianmin Liu *Shenzhen Key Laboratory of Neuroimmunomodulation for Neurological Diseases, Shenzhen- Hong Kong Institute of Brain Science, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518055, China.
Ruixiang ChenShenzhen Key Laboratory of Neuroimmunomodulation for Neurological Diseases, Shenzhen- Hong Kong Institute of Brain Science, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518055, China.
Ping ChenShenzhen Key Laboratory of Neuroimmunomodulation for Neurological Diseases, Shenzhen- Hong Kong Institute of Brain Science, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518055, China.
Min TaoShenzhen Key Laboratory of Neuroimmunomodulation for Neurological Diseases, Shenzhen- Hong Kong Institute of Brain Science, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518055, China.
Siyao LiShenzhen Key Laboratory of Neuroimmunomodulation for Neurological Diseases, Shenzhen- Hong Kong Institute of Brain Science, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518055, China.
Liping GuoShenzhen Key Laboratory of Neuroimmunomodulation for Neurological Diseases, Shenzhen- Hong Kong Institute of Brain Science, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518055, China.
Xixi ZhuShenzhen Key Laboratory of Neuroimmunomodulation for Neurological Diseases, Shenzhen- Hong Kong Institute of Brain Science, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518055, China.
Yan LiuShenzhen Key Laboratory of Neuroimmunomodulation for Neurological Diseases, Shenzhen- Hong Kong Institute of Brain Science, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518055, China.
Lu LiuHunan Provincial Key Laboratory of Animal Models and Molecular Medicine, School of Biomedical Sciences, Hunan University, Changsha, 410082, China.
Hiroki SasaguriLaboratory for Proteolytic Neuroscience, RIKEN Center for Brain Science, Wako, 351- 0198, Saitama, Japan.
Takashi SaitoDepartment of Neurocognitive Science, Institute of Brain Science, Graduate School of Medical Sciences, Nagoya City University, Nagoya, 467-8601, Aichi, Japan.
Takaomi C SaidoLaboratory for Proteolytic Neuroscience, RIKEN Center for Brain Science, Wako, 351- 0198, Saitama, Japan.
Dominic M WalshLaboratory for Neurodegenerative Research, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA.
Zhangjin ZhangDepartment of Chinese Medicine, The University of Hong Kong-Shenzhen Hospital (HKU-SZH), Shenzhen, 518055, China. zhangzj@hku.hk.
Wei HongShenzhen Key Laboratory of Neuroimmunomodulation for Neurological Diseases, Shenzhen- Hong Kong Institute of Brain Science, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518055, China. wei.hong@siat.ac.cn.

Funding

Key-Area Research and Development Program of Guangdong Province 2023B0303040004National Natural Science Foundation of China 32471010Shenzhen City's Key Medical Discipline-Department of Traditional Chinese Medicine Brain Disorders SZXK202302Shenzhen Key Laboratory of Neuroimmunomodulation for Neurological Diseases ZDSYS20220304163558001Shenzhen Science and Technology Program JCYJ20220818100802005
6 · The paper itself

Abstract

Significant data suggest that cerebral accumulation of the amyloid β-protein (Aβ) plays an initiating role in Alzheimer's disease (AD), however, Aβ can exist in multiple different forms and it is not clear which of these contribute to the propagation of amyloid or toxicity. When injected into animal models, Aβ-containing homogenates from AD or APP transgenic mouse brain accelerate amyloid pathology, but the nature of the seeding species remain ill-defined. In this study, we took advantage of well-characterized brain extracts from human AD cases and App

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesBrainAgedAged, 80 and overAmyloid beta-Protein PrecursorAnimalsDisease Models, AnimalFemaleHumansMaleMiceMice, Inbred C57BLMice, TransgenicAmyloid beta-PeptidesAmyloid beta-Protein PrecursorAmyloid β-proteinCognitive impairmentGliosisNeuronal lossNeurotoxicityPrion-like spreadingSoluble aggregates

Identifiers

PMID40410917
PMCPMC12102860

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.